Precision Medicine in Oncology® | Specialty

The OncLive Precision Medicine in Oncology® condition center page is a comprehensive resource for clinical news and expert insights on precision-focused approaches in patients with cancer, with gene-targeted tyrosine kinase inhibitors and antibody-drug conjugates, checkpoint inhibitors, tumor-infiltrating lymphocyte therapy, and other tailored treatments. This page features news articles, interviews in written and video format, and podcasts that focus on updates and ongoing research with personalized therapies across solid and hematologic tumors.

Chemotherapy Regimens for Ovarian Cancer

November 26th 2014

Goal of Surgery in Ovarian Cancer

November 26th 2014

Cytoreductive Surgery for Ovarian Cancer

November 26th 2014

Neoadjuvant Chemotherapy for Ovarian Cancer

November 26th 2014

Timing of Oophorectomy in Ovarian Cancer

November 26th 2014

Prophylactic Oophorectomy for Reducing Ovarian Cancer Risk

November 26th 2014

Universal Screening for BRCA1 and BRCA2 Mutations

November 26th 2014

Making EGFR-Positive NSCLC a Chronic Disease

November 20th 2014

Team Approach to Lung Cancer Care Is Essential

November 20th 2014

Reconsideration of Gefitinib in EGFR-Mutant NSCLC

November 20th 2014

Treating Acquired Resistance to TKIs in NSCLC

November 20th 2014

Dosing Strategies for Managing TKI-Related Side Effects

November 20th 2014

Patient-reported Outcomes with TKIs

November 20th 2014

Frontline Afatinib in EGFR-Mutant NSCLC

November 20th 2014

Frontline Treatment of Advanced NSCLC

November 20th 2014

Recommended Mutation Testing in Lung Cancer

November 20th 2014

Lung Cancer Treatment on Brink of New Molecular Era

November 10th 2014

Although testing for EGFR mutations and ALK rearrangements in patients with NSCLC has become widespread, the time has come to translate into clinical practice next-generation sequencing assays that provide exponentially more information about tumor biology.

Dr. Lynch Discusses Resistance to EGFR TKIs in Lung Cancer

November 8th 2014

Thomas J. Lynch, MD, from the Yale Cancer Center, explains how resistance occurs when treating lung cancer patients with EGFR TKIs.

New Research Focuses on Personalized Treatments in Ovarian Cancer

November 6th 2014

Translating current and emerging knowledge of the molecular drivers of ovarian cancer is yielding promising new insights into potential clinical targets, moving treatment away from historical paradigms in favor of more personalized therapeutic approaches.

Collaboration Accelerates KRAS Inhibitor Development

November 4th 2014

A novel first-in-class covalent KRAS inhibitor SML-8-73-1 has demonstrated promise in preclinical studies, prompting a 3-year research collaboration between the Dana-Farber Cancer Institute and Astellas Pharma Inc.